Skip to main content
. 2019 Jun 17;4(3):e000498. doi: 10.1136/esmoopen-2019-000498

Table 1.

Anti-PD-1 and anti-PD-L1 efficacy in patients with wild-type NSCLC versus patients with EGFR-mutated NSCLC

Study Treatment EGFR-mutated
n (%)
HR OS wild-type versus mutated patients who received anti-PD-1 or PD-L1
Check Mate 05744 Nivolumab versus docetaxel 82 (14%) 0.66 (0.51–0.85) versus 1.18 (0.45–2.07)
KEYNOTE-01082 Pembrolizumab versus docetaxel 86 (8%) 0.66 (0.55–0.79) versus 0.88 (0.45–1.72)
OAK83 Atezolizumab versus docetaxel 85 (10%) 0.69 (0.57–0.83) versus 1.24 (0.71–2.18)
POPLAR61 Atezolizumab versus docetaxel 18 (6%) 0.70 (0.47–1.04) versus 0.99 (0.29–3.40)
ImPOWER 15013 Atezolizumab plus bevacizumab and chemotherapy versuschemotherapy plus bevacizumab 80 (10%) 0.62 (0.52–0.74) versus 0.41 (0.22–0.78)

NSCLC, non-small cell lung cancer; OS, overall survival; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1.